Canadian Hemophilia Society – Bayer – ADVANCE Canada Research Program
Funder’s Website
The funder’s website can be found HERE.
Funding Value and Duration
The primary intent of this program is to offer one or two $22,500 research grants, to a maximum of $45,000 for one year.
Depending upon the number and quality of applications, funding for different amounts is possible, as is the offering of more than one research grant, within however, the allotted total budget stated above.
Overview
The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population. The research program will support studies that aim to:
- Identify and provide insight into key issues associated with the ageing hemophilia population
- Identify how management of age-related co-morbidities should be adapted to those with hemophilia
- Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia
Eligibility Criteria
To be eligible the applicant must be a physician or Ph.D., or professionals from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Applicants must be Canadian citizens or permanent residents and affiliated with a Canadian university or not-for-profit health-related organization.
The proposed research must have relevance to current practice in bleeding disorders care and may incorporate a broad spectrum of quantitative and qualitative research methods addressing professional practice with individuals, families, groups and communities, organizational issues, public health, and education.
The research studies should aim to provide better data and tools to help the treaters assist patients in successful ageing.
Interest areas and methodologies might include but are not limited to:
- musculoskeletal problems – loss of joint and muscle function and chronic pain that can impair daily activities and worsen quality of life.
- cardiovascular disease – risk factors most frequently seen in hemophilia patients include hypertension, or high blood pressure, and being overweight.
- viral infections such as HIV and hepatitis – these conditions imply treatment with antiviral drugs, which may affect patients’ kidneys and liver.
- chronic kidney disease – this condition causes hypertension. Because of hemophilia patients’ deficient blood clotting ability, it could increase their risk of a brain hemorrhage.
- chronic pain – this condition also implies treatments that could adversely affect hemophilia patients.
- cancer – chemotherapy can cause loss of white blood cells, which could worsen hemophilia patients’ tendency to bleed.
Internal Contacts
Potential applicants are encouraged to discuss this funding opportunity with their Faculty Research Facilitator.
Deadlines
| Faculty Deadline | Consult your Faculty Research Facilitator. |
| OVPRII Deadline (Approval Form and Application) | November 22, 2024 |
| Submission to Sponsor | November 29, 2024 |
Submitting Your Application
- Step 1) Submit an internal Carleton Approval Form
Submit an internal Approval Form through our central awards management database CUResearch:
https://ovpri.research.carleton.ca/Romeo.Researcher/Administrator/Default.aspx
For a user’s guide on submitting an Approval Form, click HERE. - Step 2) Submit an external application to the granting agency
Submit an external application to the corresponding grant or award agency. To navigate to the funder’s website, click HERE